Stem definition | Drug id | CAS RN |
---|---|---|
antivirals | 989 | 154598-52-4 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 27.15 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 42.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 17, 1998 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Maternal exposure during pregnancy | 1019.11 | 57.19 | 245 | 1507 | 14618 | 2341715 |
Abortion spontaneous | 693.01 | 57.19 | 177 | 1575 | 13268 | 2343065 |
Pregnancy | 677.08 | 57.19 | 157 | 1595 | 7792 | 2348541 |
Exposure during pregnancy | 501.63 | 57.19 | 158 | 1594 | 25061 | 2331272 |
Immune reconstitution inflammatory syndrome | 469.95 | 57.19 | 85 | 1667 | 1159 | 2355174 |
Abortion induced | 462.47 | 57.19 | 99 | 1653 | 3337 | 2352996 |
Stillbirth | 451.08 | 57.19 | 84 | 1668 | 1357 | 2354976 |
Normal newborn | 395.40 | 57.19 | 74 | 1678 | 1226 | 2355107 |
Viral mutation identified | 374.47 | 57.19 | 56 | 1696 | 199 | 2356134 |
Drug resistance | 372.04 | 57.19 | 79 | 1673 | 2545 | 2353788 |
Foetal exposure during pregnancy | 312.45 | 57.19 | 78 | 1674 | 5174 | 2351159 |
Virologic failure | 285.77 | 57.19 | 45 | 1707 | 241 | 2356092 |
Live birth | 265.58 | 57.19 | 53 | 1699 | 1238 | 2355095 |
Lactic acidosis | 204.74 | 57.19 | 56 | 1696 | 5274 | 2351059 |
Caesarean section | 175.99 | 57.19 | 47 | 1705 | 4034 | 2352299 |
Anaemia | 158.54 | 57.19 | 75 | 1677 | 34717 | 2321616 |
Cerebellar ataxia | 131.05 | 57.19 | 22 | 1730 | 184 | 2356149 |
Premature delivery | 129.15 | 57.19 | 35 | 1717 | 3165 | 2353168 |
Birth mark | 122.70 | 57.19 | 17 | 1735 | 28 | 2356305 |
Congenital umbilical hernia | 118.10 | 57.19 | 17 | 1735 | 42 | 2356291 |
Lipodystrophy acquired | 90.54 | 57.19 | 17 | 1735 | 282 | 2356051 |
Premature baby | 88.19 | 57.19 | 26 | 1726 | 3178 | 2353155 |
Pyrexia | 87.30 | 57.19 | 59 | 1693 | 53649 | 2302684 |
Pregnancy on contraceptive | 83.25 | 57.19 | 16 | 1736 | 302 | 2356031 |
Hepatitis fulminant | 82.76 | 57.19 | 18 | 1734 | 639 | 2355694 |
Pathogen resistance | 78.29 | 57.19 | 18 | 1734 | 825 | 2355508 |
Foetal death | 77.49 | 57.19 | 21 | 1731 | 1891 | 2354442 |
Pulmonary tuberculosis | 77.42 | 57.19 | 18 | 1734 | 867 | 2355466 |
Tuberculosis | 77.24 | 57.19 | 21 | 1731 | 1914 | 2354419 |
Autoimmune hepatitis | 70.48 | 57.19 | 19 | 1733 | 1676 | 2354657 |
Product use issue | 70.12 | 57.19 | 31 | 1721 | 12138 | 2344195 |
Vomiting | 70.01 | 57.19 | 58 | 1694 | 71544 | 2284789 |
Encephalopathy | 67.23 | 57.19 | 23 | 1729 | 4538 | 2351795 |
Treatment noncompliance | 62.88 | 57.19 | 23 | 1729 | 5511 | 2350822 |
Premature rupture of membranes | 61.43 | 57.19 | 15 | 1737 | 891 | 2355442 |
Drug level increased | 61.15 | 57.19 | 19 | 1733 | 2768 | 2353565 |
Rash | 59.72 | 57.19 | 49 | 1703 | 59509 | 2296824 |
Drug interaction | 59.43 | 57.19 | 37 | 1715 | 29126 | 2327207 |
Jaundice | 59.29 | 57.19 | 22 | 1730 | 5486 | 2350847 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 59.02 | 57.19 | 9 | 1743 | 37 | 2356296 |
Pregnancy with implant contraceptive | 58.64 | 57.19 | 13 | 1739 | 504 | 2355829 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Immune reconstitution inflammatory syndrome | 1191.32 | 40.97 | 220 | 2299 | 1329 | 1742933 |
Lipodystrophy acquired | 644.93 | 40.97 | 106 | 2413 | 267 | 1743995 |
Drug resistance | 392.18 | 40.97 | 101 | 2418 | 3129 | 1741133 |
Foetal exposure during pregnancy | 358.56 | 40.97 | 109 | 2410 | 6250 | 1738012 |
Mitochondrial toxicity | 276.01 | 40.97 | 47 | 2472 | 155 | 1744107 |
Hyperlipidaemia | 271.67 | 40.97 | 70 | 2449 | 2159 | 1742103 |
Pyrexia | 258.38 | 40.97 | 152 | 2367 | 46248 | 1698014 |
Viral mutation identified | 234.14 | 40.97 | 45 | 2474 | 333 | 1743929 |
Virologic failure | 224.80 | 40.97 | 44 | 2475 | 362 | 1743900 |
Progressive external ophthalmoplegia | 222.07 | 40.97 | 33 | 2486 | 27 | 1744235 |
Lipoatrophy | 186.78 | 40.97 | 31 | 2488 | 83 | 1744179 |
Eyelid ptosis | 182.19 | 40.97 | 41 | 2478 | 696 | 1743566 |
Hyperlactacidaemia | 177.56 | 40.97 | 36 | 2483 | 360 | 1743902 |
Pulmonary tuberculosis | 167.14 | 40.97 | 41 | 2478 | 1025 | 1743237 |
Anaemia | 159.16 | 40.97 | 95 | 2424 | 29362 | 1714900 |
Depression | 145.86 | 40.97 | 74 | 2445 | 16595 | 1727667 |
Hepatitis | 141.64 | 40.97 | 51 | 2468 | 4904 | 1739358 |
Alanine aminotransferase increased | 138.90 | 40.97 | 65 | 2454 | 12213 | 1732049 |
Diplopia | 135.63 | 40.97 | 42 | 2477 | 2528 | 1741734 |
Hepatic function abnormal | 134.30 | 40.97 | 54 | 2465 | 7020 | 1737242 |
Aspartate aminotransferase increased | 131.16 | 40.97 | 60 | 2459 | 10696 | 1733566 |
Rash | 130.75 | 40.97 | 93 | 2426 | 38600 | 1705662 |
Diarrhoea | 121.94 | 40.97 | 102 | 2417 | 53750 | 1690512 |
Gamma-glutamyltransferase increased | 121.81 | 40.97 | 46 | 2473 | 5052 | 1739210 |
Vomiting | 120.05 | 40.97 | 88 | 2431 | 38227 | 1706035 |
Lactic acidosis | 114.33 | 40.97 | 44 | 2475 | 5085 | 1739177 |
Gynaecomastia | 113.13 | 40.97 | 35 | 2484 | 2097 | 1742165 |
Drug-induced liver injury | 110.33 | 40.97 | 38 | 2481 | 3199 | 1741063 |
Lymphadenopathy | 108.79 | 40.97 | 40 | 2479 | 4074 | 1740188 |
Abnormal dreams | 108.64 | 40.97 | 33 | 2486 | 1858 | 1742404 |
Hypertriglyceridaemia | 104.57 | 40.97 | 29 | 2490 | 1180 | 1743082 |
Hepatic fibrosis | 102.77 | 40.97 | 25 | 2494 | 601 | 1743661 |
Acute kidney injury | 102.05 | 40.97 | 77 | 2442 | 34867 | 1709395 |
Meningitis cryptococcal | 100.54 | 40.97 | 22 | 2497 | 325 | 1743937 |
Renal impairment | 99.84 | 40.97 | 52 | 2467 | 12262 | 1732000 |
Blood triglycerides increased | 94.36 | 40.97 | 32 | 2487 | 2568 | 1741694 |
Drug interaction | 93.73 | 40.97 | 67 | 2452 | 27891 | 1716371 |
General physical health deterioration | 85.66 | 40.97 | 48 | 2471 | 13070 | 1731192 |
Hepatotoxicity | 85.26 | 40.97 | 31 | 2488 | 3053 | 1741209 |
Nervous system disorder | 84.34 | 40.97 | 29 | 2490 | 2425 | 1741837 |
Premature baby | 82.93 | 40.97 | 30 | 2489 | 2912 | 1741350 |
Blood alkaline phosphatase increased | 82.70 | 40.97 | 35 | 2484 | 5160 | 1739102 |
Kaposi's sarcoma | 80.52 | 40.97 | 22 | 2497 | 845 | 1743417 |
Hypercholesterolaemia | 77.58 | 40.97 | 23 | 2496 | 1189 | 1743073 |
Nightmare | 76.98 | 40.97 | 28 | 2491 | 2759 | 1741503 |
Portal hypertension | 75.95 | 40.97 | 20 | 2499 | 666 | 1743596 |
Blood HIV RNULL increased | 75.81 | 40.97 | 16 | 2503 | 197 | 1744065 |
Jaundice | 74.34 | 40.97 | 34 | 2485 | 6028 | 1738234 |
Proteinuria | 72.73 | 40.97 | 27 | 2492 | 2817 | 1741445 |
Weight decreased | 72.67 | 40.97 | 53 | 2466 | 22700 | 1721562 |
Asthenia | 72.66 | 40.97 | 63 | 2456 | 34607 | 1709655 |
Treatment failure | 71.19 | 40.97 | 30 | 2489 | 4371 | 1739891 |
Insomnia | 71.08 | 40.97 | 46 | 2473 | 16230 | 1728032 |
Nausea | 71.02 | 40.97 | 74 | 2445 | 51122 | 1693140 |
Hepatomegaly | 70.12 | 40.97 | 23 | 2496 | 1662 | 1742600 |
Cholestasis | 69.52 | 40.97 | 28 | 2491 | 3637 | 1740625 |
Nephropathy toxic | 69.49 | 40.97 | 23 | 2496 | 1709 | 1742553 |
Pneumocystis jirovecii pneumonia | 69.04 | 40.97 | 25 | 2494 | 2431 | 1741831 |
Cachexia | 68.17 | 40.97 | 20 | 2499 | 996 | 1743266 |
Liver disorder | 67.18 | 40.97 | 31 | 2488 | 5605 | 1738657 |
Pathogen resistance | 66.80 | 40.97 | 20 | 2499 | 1069 | 1743193 |
Cytomegalovirus chorioretinitis | 66.05 | 40.97 | 16 | 2503 | 377 | 1743885 |
Renal failure | 64.73 | 40.97 | 47 | 2472 | 19970 | 1724292 |
Cryptococcosis | 64.21 | 40.97 | 15 | 2504 | 301 | 1743961 |
Osteonecrosis | 64.05 | 40.97 | 27 | 2492 | 3935 | 1740327 |
Tuberculosis | 63.90 | 40.97 | 22 | 2497 | 1844 | 1742418 |
Neuropathy peripheral | 63.47 | 40.97 | 35 | 2484 | 9218 | 1735044 |
Mycobacterium avium complex infection | 63.21 | 40.97 | 15 | 2504 | 323 | 1743939 |
HIV infection | 61.47 | 40.97 | 14 | 2505 | 250 | 1744012 |
Headache | 61.18 | 40.97 | 57 | 2462 | 34319 | 1709943 |
Diabetes mellitus | 61.18 | 40.97 | 31 | 2488 | 6877 | 1737385 |
Dyspnoea | 59.51 | 40.97 | 68 | 2451 | 51991 | 1692271 |
Hepatitis B | 57.76 | 40.97 | 19 | 2500 | 1384 | 1742878 |
Decreased appetite | 57.38 | 40.97 | 47 | 2472 | 23824 | 1720438 |
Hypertension | 56.89 | 40.97 | 43 | 2476 | 19405 | 1724857 |
Hepatic cirrhosis | 56.35 | 40.97 | 22 | 2497 | 2631 | 1741631 |
Abdominal pain | 55.21 | 40.97 | 44 | 2475 | 21446 | 1722816 |
Hypophosphataemia | 55.00 | 40.97 | 18 | 2501 | 1290 | 1742972 |
Oral candidiasis | 54.99 | 40.97 | 18 | 2501 | 1291 | 1742971 |
CD4 lymphocytes decreased | 54.36 | 40.97 | 14 | 2505 | 426 | 1743836 |
Hepatosplenomegaly | 53.77 | 40.97 | 15 | 2504 | 622 | 1743640 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 53.18 | 40.97 | 9 | 2510 | 28 | 1744234 |
Liver injury | 52.29 | 40.97 | 19 | 2500 | 1863 | 1742399 |
Ophthalmoplegia | 52.08 | 40.97 | 12 | 2507 | 226 | 1744036 |
Hypokalaemia | 51.80 | 40.97 | 27 | 2492 | 6347 | 1737915 |
Intracranial pressure increased | 51.29 | 40.97 | 15 | 2504 | 738 | 1743524 |
Meningitis tuberculous | 50.73 | 40.97 | 10 | 2509 | 85 | 1744177 |
Viral load increased | 50.43 | 40.97 | 14 | 2505 | 570 | 1743692 |
Hepatic steatosis | 49.88 | 40.97 | 20 | 2499 | 2564 | 1741698 |
Renal tubular disorder | 49.07 | 40.97 | 15 | 2504 | 860 | 1743402 |
Blood lactic acid increased | 48.67 | 40.97 | 15 | 2504 | 884 | 1743378 |
Sepsis | 48.21 | 40.97 | 39 | 2480 | 19399 | 1724863 |
Myocardial infarction | 48.17 | 40.97 | 45 | 2474 | 27129 | 1717133 |
Amylase increased | 47.72 | 40.97 | 16 | 2503 | 1236 | 1743026 |
Developmental hip dysplasia | 47.71 | 40.97 | 9 | 2510 | 59 | 1744203 |
Sleep disorder | 47.31 | 40.97 | 22 | 2497 | 4041 | 1740221 |
Confusional state | 47.17 | 40.97 | 40 | 2479 | 21238 | 1723024 |
HIV-associated neurocognitive disorder | 46.95 | 40.97 | 9 | 2510 | 65 | 1744197 |
Congenital umbilical hernia | 46.83 | 40.97 | 9 | 2510 | 66 | 1744196 |
Oesophageal candidiasis | 46.23 | 40.97 | 13 | 2506 | 555 | 1743707 |
Blood creatine phosphokinase increased | 46.07 | 40.97 | 28 | 2491 | 8828 | 1735434 |
Liver transplant | 45.40 | 40.97 | 13 | 2506 | 593 | 1743669 |
Nodular regenerative hyperplasia | 45.23 | 40.97 | 10 | 2509 | 155 | 1744107 |
Malaise | 44.95 | 40.97 | 45 | 2474 | 29520 | 1714742 |
Dizziness | 44.53 | 40.97 | 48 | 2471 | 34313 | 1709949 |
Progressive multifocal leukoencephalopathy | 43.50 | 40.97 | 16 | 2503 | 1623 | 1742639 |
Low density lipoprotein increased | 43.44 | 40.97 | 14 | 2505 | 955 | 1743307 |
Fanconi syndrome | 42.86 | 40.97 | 11 | 2508 | 330 | 1743932 |
Psychotic disorder | 42.74 | 40.97 | 22 | 2497 | 5034 | 1739228 |
Hepatitis C | 41.68 | 40.97 | 18 | 2501 | 2778 | 1741484 |
Exposure during pregnancy | 41.56 | 40.97 | 18 | 2501 | 2799 | 1741463 |
Dyslipidaemia | 41.44 | 40.97 | 13 | 2506 | 812 | 1743450 |
Source | Code | Description |
---|---|---|
ATC | J05AG03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors |
ATC | J05AR06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA EPC | N0000175463 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
FDA EXT | N0000175460 | Non-Nucleoside Analog |
FDA MoA | N0000009948 | Non-Nucleoside Reverse Transcriptase Inhibitors |
FDA MoA | N0000190118 | Cytochrome P450 3A Inducers |
FDA MoA | N0000187064 | Cytochrome P450 2B6 Inducers |
FDA MoA | N0000185504 | Cytochrome P450 2C9 Inhibitors |
FDA MoA | N0000182140 | Cytochrome P450 2C19 Inhibitors |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drug |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D065695 | Cytochrome P-450 CYP2B6 Inducers |
MeSH PA | D065689 | Cytochrome P-450 CYP2C19 Inhibitors |
MeSH PA | D065688 | Cytochrome P-450 CYP2C9 Inhibitors |
MeSH PA | D065701 | Cytochrome P-450 CYP3A Inducers |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Osteomalacia | contraindication | 4598005 | DOID:10573 |
Hypophosphatemia | contraindication | 4996001 | |
Suicidal thoughts | contraindication | 6471006 | |
Hypercholesterolemia | contraindication | 13644009 | |
Depressive disorder | contraindication | 35489007 | |
Fanconi syndrome | contraindication | 40488004 | DOID:1062 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Aggressive behavior | contraindication | 61372001 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Chronic hepatitis C | contraindication | 128302006 | |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Paranoid disorder | contraindication | 191667009 | |
Steatosis of liver | contraindication | 197321007 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pathological fracture | contraindication | 268029009 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Osteopenia | contraindication | 312894000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.6 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 6642245 | Nov. 4, 2020 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 6642245 | Nov. 4, 2020 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8592397 | Jan. 13, 2024 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8592397 | Jan. 13, 2024 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8716264 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9457036 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9744181 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9018192 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9018192 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9545414 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9545414 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Reverse transcriptase/RNaseH | Enzyme | INHIBITOR | Ki | 8.52 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | INHIBITOR | IC50 | 8.30 | WOMBAT-PK | ||||
Reverse transcriptase | Enzyme | IC50 | 8.89 | CHEMBL |
ID | Source |
---|---|
4021133 | VUID |
N0000148587 | NUI |
C0674428 | UMLSCUI |
D00896 | KEGG_DRUG |
116078005 | SNOMEDCT_US |
d04355 | MMSL |
7492 | MMSL |
195085 | RXNORM |
4021133 | VANDF |
387001004 | SNOMEDCT_US |
007651 | NDDF |
210786 | MMSL |
CHEMBL223228 | ChEMBL_ID |
DB00625 | DRUGBANK_ID |
JE6H2O27P8 | UNII |
7718 | INN_ID |
EFZ | PDB_CHEM_ID |
CHEBI:119486 | CHEBI |
64139 | PUBCHEM_CID |
C098320 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0470 | CAPSULE, GELATIN COATED | 50 mg | ORAL | NDA | 20 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0474 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 20 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0510 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 20 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2233 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 15584-0101 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 20 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-504 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
SYMFI LO | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49502-425 | TABLET, FILM COATED | 400 mg | ORAL | NDA | 19 sections |
SYMFI | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49502-475 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 19 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 53808-0208 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 20 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4668 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 18 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 54868-5643 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 20 sections |
Atripla Access | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-1601 | TABLET, FILM COATED | 600 mg | ORAL | EXPORT ONLY | 20 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-889 | TABLET | 600 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-406 | CAPSULE | 50 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-407 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-049 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-104 | CAPSULE | 50 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-105 | CAPSULE | 100 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-106 | CAPSULE | 200 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65862-774 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-301 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 70518-0341 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 20 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1013 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 18 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1100 | TABLET | 600 mg | ORAL | ANDA | 18 sections |